The Journal of Clinical Endocrinology & Metabolism, 79(5), 1361-1366
Furthermore, limited diagnostic capabilities, difficulty in identifying eligible patients, and variability in disease progression collectively contribute to low enrollment rates, prolonged study timelines, and compromised data integrity in rare disease trials, ultimately resulting in higher failure rates compared to non-rare disease trials 5,6
CAS 42464-96-0 uniquely identifies the compound 5-Amino-1MQ for accurate chemical documentation and research reproducibility
The FDA has approved multiple therapeutic classes for Crohn's disease management, with treatment selection based on disease severity, location, phenotype (inflammatory, stricturing, or penetrating), and prior treatment response
GSH dose-dependently downregulated Bax, whereas Bcl-2 was upregulated
Wang B, Chen J, Wang S, et al